Peer-reviewedCC BY 4.0Frontiers in Oncology
Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America
11 affiliations
- 1Centro de Investigación y Manejo del Cáncer (CIMCA)
- 2Oncology Service, Clinica AMO
- 3Centro de Educación Médica de Investigaciones Clínicas (CEMIC)
- 4Oncosalud-AUNA
- 5Oncology Department, Clínica Alemana
- 6Medical Oncology Department, Oncare
- 7Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC)
- 8Clinical Oncology Unit, Centro de excelencia tumores torácicos, Clínica las Américas-AUNA
- 9Medical Oncology Department, Instituto Nacional de Cancerología
- 10Medical Oncology Service, Instituto Alexander Fleming
- 11Oncology Department, Hospital Sírio-Libanês
Abstract
Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) that has been shown to have high efficacy in the first line setting for treatment of advanced ALK-rearranged non-small cell lung cancer (NSCLC). However, some adverse events have been described that require proper follow-up and management to obtain the maximum benefit from treatment and minimize risk to the patient. These include dyslipidemia and weight gain, conditions that in Latin America have a high prevalence in the general population, which coupled with limitations in timely access to specialized care, could influence both manifestation and management. The objective of this consensus is to provide recommendations tailored to our real-world setting that will optimize the monitoring and early management of toxicities in patients treated with lorlatinib in Latin America.
Related
- Actions, recommendations, and public policy solutions for the management of dermatological diseases in Latin America: a systematic review
- A critical appraisal of guidelines and recommendations for the management of ANCA-associated vasculitis.
- Focused Update to International Consensus Recommendations for the Use of Prolonged‐Infusion Beta‐Lactam Antibiotics Among Severely Ill Adult Patients: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists
- Early Toxicities of CAR-T Cell Therapy: Mechanisms, Prediction, and Management
- Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome
BibTeX
@article{corrales2026expert,
title = {{Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America}},
author = {Luis Corrales and Aknar Freire de Carvalho Calabrich and Aldo Agustin Perfetti and Luis Alberto Mas López and Javier Quilodran Peredo and Lizbett Vanessa Garcia Montes and Andrés Felipe Cardona Zorrilla and Sergio Andrés Mejía Espinosa and Maritza Ramos-Pérez and Carmen Sofía Pupareli and Gulherme Harada},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1740218},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1740218/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America
AU - Luis Corrales
AU - Aknar Freire de Carvalho Calabrich
AU - Aldo Agustin Perfetti
AU - Luis Alberto Mas López
AU - Javier Quilodran Peredo
AU - Lizbett Vanessa Garcia Montes
AU - Andrés Felipe Cardona Zorrilla
AU - Sergio Andrés Mejía Espinosa
AU - Maritza Ramos-Pérez
AU - Carmen Sofía Pupareli
AU - Gulherme Harada
PY - 2026
DA - 2026/10/26
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1740218
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1740218/full
AB - Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor (TKI) that has been shown to have high efficacy in the first line setting for treatment of advanced ALK-rearranged non-small cell lung cancer (NSCLC). However, some adverse events have been described that require proper follow-up and management to obtain the maximum benefit from treatment and minimize risk to the patient. These include dyslipidemia and weight gain, conditions that in Latin America have a high prevalence in the general population, which coupled with limitations in timely access to specialized care, could influence both manifestation and management. The objective of this consensus is to provide recommendations tailored to our real-world setting that will optimize the monitoring and early management of toxicities in patients treated with lorlatinib in Latin America.
SN - 2234-943X
ER -